Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Low-Dose Docetaxel in Platinum-Resistant Ovarian Cancer
NCT00004081Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jul 1999
- Primary completion
- Jan 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in ovarian epithelial cancer, primary peritoneal serous carcinoma (PPSC), sponsored by Beth Israel Deaconess Medical Center. Started Jul 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
ovarian epithelial cancerprimary peritoneal serous carcinoma (PPSC)
Beyond the preview
Go deeper on NCT00004081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004081.